Antimicrobial resistance (AMR) remains one of the most pressing global health threats, jeopardizing both modern medicine and the achievement of the Sustainable Development Goals. Every year, millions of lives are affected by infections caused by resistant bacteria, and it is estimated that, without urgent action, AMR could cause up to 10 million deaths annually by 2050.
In this context, BioClonal joins the global effort through a “One Health” approach, addressing human, animal, and environmental health in an integrated manner. Our commitment focuses on the development of advanced therapies—such as RNA-based oligonucleotides and cell therapies—that offer innovative mechanisms to combat AMR. We also invest in rapid diagnostic tools that enable early detection of resistance directly from clinical samples.
By accelerating diagnosis and promoting targeted treatments, we help reduce the inappropriate use of antibiotics and limit the spread of resistant infections, offering differentiated solutions in a landscape where urgency is paramount.
Funding Agency: Funded by CDTI and supported by the Ministry of Science and Innovation
Beneficiary: BIOCLONAL S.L.
Partners: CERTEST BIOTEC, S.L.; NOSTRUM BIODISCOVERY S.L.; HIBERUS TECNOLOGIAS DIFERENCIALES SL; LEVPROT BIOSCIENCE SL; POLYPEPTIDE THERAPEUTIC SOLUTIONS SL; ISCIII; FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL; CSIC-CIB; IRB BARCELONA; FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
Duration: January 2025 – December 2028